GlassScriptPhysician profile
Christopher Paul Downing
NPI 1780939405
$6,768.89
in general payments reported to CMS, 2019-2025
34 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $787 · 2021: $497 · 2022: $496 · 2023: $1,773 · 2024: $421 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.05 |
| Education | $147.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.73 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $675.32 | 2019-2021 | |
| Amgen INC. | $674.43 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $579.41 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $522.36 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $480.62 | 2019-2023 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $375.69 | 2019-2023 | Oracea, Aklief, Twyneo |
| Janssen Biotech, INC. | $368.37 | 2019-2025 | Tremfya |
| Genzyme Corporation | $322.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $274.28 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $225.42 | 2022-2023 | Vtama |
| Encore Dermatology INC. | $173.40 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.45 | 2019-2023 | Targretin, Siliq |
| Celgene Corporation | $157.43 | 2019 | |
| Incyte Corporation | $150.07 | 2023 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $87.61 | 2019-2023 | |
| Convatec INC. | $76.28 | 2024-2025 | |
| Strata Skin Sciences, INC. | $72.97 | 2019-2023 | Xtrac |
| Bioventus LLC | $67.76 | 2022-2023 | |
| Ucb, INC. | $62.93 | 2020-2023 | Cimzia |
| Almirall LLC | $50.00 | 2019 | |
| Medline Industries LP | $48.76 | 2022 | |
| Vyne Pharmaceuticals INC. | $39.63 | 2020 | |
| Leo Pharma INC. | $34.69 | 2019-2023 | Adbry |
| Hill Dermaceuticals, INC. | $32.00 | 2022 | |
| Mylan Pharmaceuticals INC. | $30.37 | 2019 | |
| Merz North America, INC. | $25.50 | 2020 | |
| Mayne Pharma Commercial LLC | $21.36 | 2020 | |
| Kerecis Limited | $19.18 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Dermira, INC. | $18.26 | 2020 | |
| Mimedx Group, INC. | $17.97 | 2024 | |
| Genentech USA, INC. | $16.44 | 2024 | Erivedge |
| Merck Sharp & Dohme LLC | $11.36 | 2019 | |
| Organon LLC | $8.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.